Status:
COMPLETED
Evaluation of Airway Pressure Release Ventilation in COVID-19 ARDS
Lead Sponsor:
Central Hospital, Nancy, France
Conditions:
ARDS
COVID19
Eligibility:
All Genders
18+ years
Brief Summary
The 2020 pandemic of the coronavirus (SARS-CoV2) has lead to an increase in ARDS cases requiring invasive mechanical ventilation in the ICU (Intensive Care Unit). The investigators hypothesize that a...
Detailed Description
Lung protective mechanical ventilation is the cornerstone of ARDS management, reducing the work of respiratory muscles and optimizing gas exchange. However, it can be the source of deleterious effects...
Eligibility Criteria
Inclusion
- Patients treated in Nancy University Hospital between 01/04/2020 and 31/06/2020 for COVID-19 ARDS, requiring invasive ventilation
- Trial of airway pressure release ventilation during the ICU stay
Exclusion
- Patients requiring veno-venous ECMO
- Patients unable to complete the 6-hour APRV trial due to poor tolerance : SpO2 decrease \< 90% on FiO2 70%, haemodynamic instability (MAP \< 65mmhg without vasopressors, or 0.5 mg/h increase in norepinephrine, ventilator asynchrony (respiratory rate \>35), hypercapnia (pH \< 7,25 or PaCO2 \>60mmHg)
Key Trial Info
Start Date :
April 15 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2020
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT04386369
Start Date
April 15 2020
End Date
June 1 2020
Last Update
September 14 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier Régional Universitaire de Nancy
Nancy, France, 54500